Loading clinical trials...
Loading clinical trials...
An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.
Conditions
Interventions
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Locations
17
Argentina
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Capital Federal, Argentina
Local Institution
Cali, Colombia
Local Institution
Colima, Colima, Mexico
Local Institution
Guadalajara, Jalisco, Mexico
Local Institution
Guadalajara, Jalisco, Mexico
Start Date
February 1, 2007
Primary Completion Date
December 1, 2011
Completion Date
July 1, 2013
Last Updated
April 29, 2014
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT05897099
NCT06665646
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions